PE20040959A1 - Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion - Google Patents

Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion

Info

Publication number
PE20040959A1
PE20040959A1 PE2004000206A PE2004000206A PE20040959A1 PE 20040959 A1 PE20040959 A1 PE 20040959A1 PE 2004000206 A PE2004000206 A PE 2004000206A PE 2004000206 A PE2004000206 A PE 2004000206A PE 20040959 A1 PE20040959 A1 PE 20040959A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
acetic acid
cycloalkylmetoxi
procedures
Prior art date
Application number
PE2004000206A
Other languages
English (en)
Spanish (es)
Inventor
Hans-Ludwig Schaefer
Heiner Glombik
Dirk Gretzke
Jochen Goerlitzer
Eugen Falk
Stefanie Keil
Christian Stapper
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20040959A1 publication Critical patent/PE20040959A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PE2004000206A 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion PE20040959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20040959A1 true PE20040959A1 (es) 2005-01-17

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2004000205A PE20050293A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
PE2004000206A PE20040959A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
PE2004000203A PE20050292A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2004000205A PE20050293A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2004000203A PE20050292A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos

Country Status (34)

Country Link
US (5) US7335671B2 (US07365084-20080429-C00034.png)
EP (3) EP1599453B1 (US07365084-20080429-C00034.png)
JP (3) JP2006519199A (US07365084-20080429-C00034.png)
KR (3) KR20050105492A (US07365084-20080429-C00034.png)
CN (3) CN100439345C (US07365084-20080429-C00034.png)
AR (3) AR043427A1 (US07365084-20080429-C00034.png)
AT (3) ATE435217T1 (US07365084-20080429-C00034.png)
AU (3) AU2004215673B2 (US07365084-20080429-C00034.png)
BR (3) BRPI0407758A (US07365084-20080429-C00034.png)
CA (3) CA2517386A1 (US07365084-20080429-C00034.png)
CL (2) CL2004000392A1 (US07365084-20080429-C00034.png)
CO (2) CO5690578A2 (US07365084-20080429-C00034.png)
DE (4) DE10308355A1 (US07365084-20080429-C00034.png)
DK (3) DK1599455T3 (US07365084-20080429-C00034.png)
EC (2) ECSP055986A (US07365084-20080429-C00034.png)
ES (3) ES2329366T3 (US07365084-20080429-C00034.png)
HR (3) HRP20050743A2 (US07365084-20080429-C00034.png)
IL (2) IL170316A (US07365084-20080429-C00034.png)
MA (3) MA27742A1 (US07365084-20080429-C00034.png)
MX (3) MXPA05008988A (US07365084-20080429-C00034.png)
NO (3) NO20054408L (US07365084-20080429-C00034.png)
OA (2) OA13035A (US07365084-20080429-C00034.png)
PA (1) PA8596801A1 (US07365084-20080429-C00034.png)
PE (3) PE20050293A1 (US07365084-20080429-C00034.png)
PL (3) PL378130A1 (US07365084-20080429-C00034.png)
PT (3) PT1599455E (US07365084-20080429-C00034.png)
RS (1) RS20050594A (US07365084-20080429-C00034.png)
RU (3) RU2005129995A (US07365084-20080429-C00034.png)
SA (1) SA04250153A (US07365084-20080429-C00034.png)
TN (2) TNSN05204A1 (US07365084-20080429-C00034.png)
TW (3) TW200510352A (US07365084-20080429-C00034.png)
UY (2) UY28209A1 (US07365084-20080429-C00034.png)
WO (3) WO2004076428A1 (US07365084-20080429-C00034.png)
ZA (2) ZA200505768B (US07365084-20080429-C00034.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
KR101398715B1 (ko) 2006-08-10 2014-05-27 가부시키가이샤 미모잭스 아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물
JP5340287B2 (ja) 2007-08-16 2013-11-13 ソルヴェイ(ソシエテ アノニム) 4−フルオロ置換3−オキソ−アルカン酸のエステル類の調製方法
ES2574159T3 (es) 2008-02-29 2016-06-15 Nissan Chemical Industries, Ltd. Proceso para la producción de compuesto de tiofeno e intermedio del mismo
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
BR112020011659A2 (pt) 2017-12-13 2020-11-17 Canon Kabushiki Kaisha cartucho e aparelho de formação de imagem
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
IL125071A0 (en) 1996-01-17 1999-01-26 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP4339402B2 (ja) 1996-12-31 2009-10-07 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
DE60027420T2 (de) * 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
WO2001004146A2 (en) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
EP1204654B1 (en) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazines: 5-ht2c serotonin receptor agonists
IL148148A0 (en) * 1999-09-01 2002-09-12 Aventis Pharma Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
WO2001040171A1 (en) 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
HU229042B1 (en) 2000-03-31 2013-07-29 Prosidion Ltd Method for the improvement of islet signaling in diabetes mellitus and for its prevention
CZ20023502A3 (cs) 2000-04-25 2003-06-18 Kyorin Pharmaceutical Co., Ltd. Nová stabilní krystalická forma thiazolidionového derivátu a způsob jeho přípravy
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
BR0110638A (pt) 2000-05-11 2003-03-25 Bristol Myers Squibb Co Análogos de tetraidroisoquinolina úteis como secretagogos de hormÈnio do crescimento
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
WO2001094300A1 (de) * 2000-06-09 2001-12-13 Aventis Pharma Deutschland Gmbh Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
WO2002016331A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
DE50111751D1 (de) 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
ATE370130T1 (de) * 2000-12-25 2007-09-15 Ono Pharmaceutical Co Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
EE05418B1 (et) 2001-08-31 2011-06-15 Aventis Pharma Deutschland Gmbh Diarltskloalklderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
EP1474385B1 (en) 2002-02-05 2009-06-10 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
CA2517386A1 (en) 2004-09-10
UY28209A1 (es) 2004-09-30
AR043432A1 (es) 2005-07-27
OA13034A (en) 2006-11-10
PT1599452E (pt) 2007-09-12
EP1599452A1 (de) 2005-11-30
BRPI0407814A (pt) 2006-02-14
CN1753881A (zh) 2006-03-29
PL377735A1 (pl) 2006-02-20
SA04250153A (ar) 2005-12-03
CN100439345C (zh) 2008-12-03
CO5690578A2 (es) 2006-10-31
NO20054396L (no) 2005-11-11
ES2326418T3 (es) 2009-10-09
WO2004076428A1 (de) 2004-09-10
AU2004215673A1 (en) 2004-09-10
JP2006519193A (ja) 2006-08-24
RU2005129995A (ru) 2006-01-27
ZA200505765B (en) 2006-05-31
US20080015238A1 (en) 2008-01-17
US20050215596A1 (en) 2005-09-29
CN1756748A (zh) 2006-04-05
DK1599453T3 (da) 2009-08-24
CA2517381A1 (en) 2004-09-10
ATE435217T1 (de) 2009-07-15
NO20054398D0 (no) 2005-09-22
AR043433A1 (es) 2005-07-27
MA27736A1 (fr) 2006-02-01
DK1599455T3 (da) 2009-11-09
KR20050106462A (ko) 2005-11-09
US7365084B2 (en) 2008-04-29
CA2516620A1 (en) 2004-09-10
BRPI0407758A (pt) 2006-02-14
NO20054396D0 (no) 2005-09-22
NO20054398L (no) 2005-11-02
PL378437A1 (pl) 2006-04-03
AU2004215677B2 (en) 2010-01-07
PE20050293A1 (es) 2005-05-24
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
TNSN05204A1 (en) 2007-06-11
MXPA05008995A (es) 2005-10-18
NO20054408D0 (no) 2005-09-22
DE502004009453D1 (de) 2009-06-18
HRP20050742A2 (en) 2006-09-30
EP1599453B1 (de) 2009-05-06
UY28210A1 (es) 2004-09-30
US7335671B2 (en) 2008-02-26
US7872034B2 (en) 2011-01-18
EP1599455B1 (de) 2009-07-01
DE502004004139D1 (de) 2007-08-02
HRP20050744A2 (en) 2006-09-30
DK1599452T3 (da) 2007-10-01
TW200500349A (en) 2005-01-01
BRPI0407907A (pt) 2006-02-14
EP1599453A1 (de) 2005-11-30
AU2004215677A1 (en) 2004-09-10
ATE430738T1 (de) 2009-05-15
RS20050594A (en) 2007-12-31
US7259177B2 (en) 2007-08-21
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
CL2004000392A1 (es) 2005-04-22
EP1599452B1 (de) 2007-06-20
TNSN05206A1 (en) 2007-06-11
MA27742A1 (fr) 2006-02-01
AU2004215672B2 (en) 2010-01-07
ATE365159T1 (de) 2007-07-15
MA27737A1 (fr) 2006-02-01
OA13035A (en) 2006-11-10
US20050101637A1 (en) 2005-05-12
KR20050106461A (ko) 2005-11-09
CN100398526C (zh) 2008-07-02
DE10308355A1 (de) 2004-12-23
RU2005129992A (ru) 2006-02-10
JP2006519194A (ja) 2006-08-24
JP2006519199A (ja) 2006-08-24
ZA200505768B (en) 2005-11-23
AR043427A1 (es) 2005-07-27
KR20050105492A (ko) 2005-11-04
ECSP055986A (es) 2006-01-16
PT1599455E (pt) 2009-09-29
DE502004009690D1 (de) 2009-08-13
ES2329366T3 (es) 2009-11-25
MXPA05008951A (es) 2005-11-04
PE20050292A1 (es) 2005-05-24
ES2287700T3 (es) 2007-12-16
WO2004076427A1 (de) 2004-09-10
AU2004215673B2 (en) 2009-10-01
PT1599453E (pt) 2009-07-14
CN1753879A (zh) 2006-03-29
CO5690580A2 (es) 2006-10-31
CL2004000391A1 (es) 2005-01-07
RU2005130002A (ru) 2006-01-27
TW200510352A (en) 2005-03-16
US20040209920A1 (en) 2004-10-21
CN100439347C (zh) 2008-12-03
AU2004215672A1 (en) 2004-09-10
TW200508210A (en) 2005-03-01
IL170314A (en) 2010-11-30
US20080167354A1 (en) 2008-07-10
ECSP055985A (es) 2006-01-16
MXPA05008988A (es) 2005-10-18
PL378130A1 (pl) 2006-03-06
WO2004076426A1 (de) 2004-09-10
EP1599455A1 (de) 2005-11-30

Similar Documents

Publication Publication Date Title
PE20040959A1 (es) Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
PE20061348A1 (es) DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR029919A1 (es) Fenil sulfamoil carboxamidas sustituidas con uracilo
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
AR033791A1 (es) Compuestos de acidos oxamicos y derivados como ligandos de receptores tiroideos,su uso. composicion y estuche que lo contiene
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20100093A1 (es) Derivados de acetileno
AR045955A1 (es) Compuestos benzoimidazolicos
PE20050265A1 (es) Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1)
ES2184482T3 (es) Benzazoles, derivados del venzoxazol, el benzotiazol y el bencimidazol.
AR047329A1 (es) Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico
PE20070798A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
NI200600257A (es) Nuevos compuestos.
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos

Legal Events

Date Code Title Description
FC Refusal